Our commitment to quality: batch by batch
Avextra offers high-quality cannabis-based medicines. Our strength lies within our cultivation in Portugal and the combination of traditional and high-tech extraction methods in Germany. Discover more insights from our CMO David Reckeweg-Lecompte by watching this video.
A selection of other videos
Compiled from the various subject areas.
Reflecting on a remarkable and successful year at Avextra. We’re ready for another year of achievements in 2024.
Avextra combines decades of experience in plant-based pharmaceutical production with innovative manufacturing processes. Our experts harness the therapeutic potential of the cannabis plant to improve patients' quality of life.
Avextra offers high-quality cannabis-based medicines. Our strength lies within our cultivation in Portugal and the combination of traditional and high-tech extraction methods in Germany. Discover more insights from our CMO David Reckeweg-Lecompte by watching this video.
At Avextra, we focus on research and development of cannabis medicine to create innovative dosage forms and drive evidence-based research. Learn more with this video.
Hear from Avextra’s experts how we are setting new standards in cannabis medicine and realizing the full potential of the plant in this video clip.
Check out our state-of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes tour!
Our 2022 highlight video gives a sneak peek at some of the exciting things we've been working on and hints at what's to come.
Europe’s leader in Cannabis-based medicine
Das komplette Interview zu möglichen Vorteilen der Therapie mit medizinischem Cannabis finden Sie im Media Center für Fachkreise.
Das komplette Interview über den Einsatz von Cannabis-Medizin in der Palliativmedizin finden Sie im Media Center für Fachkreise.
Das komplette Interview zum möglichen Einsatz von Cannabis-Medizin in der Kinderpalliativversorgung finden Sie im Media Center für Fachkreise.
Podcasts
Neil Smith featured on Planted with Sara Payan.
Sara discusses the European cannabis landscape and new movement in R&D with Neil Smith, COO of German bio-pharmaceutical company Avextra.
Press Releases
Please find the latest press releases from Avextra here.
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…
Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie
In Folge einer Krebsbehandlung leiden 60-80% aller Onkologiepatientinnen und -patienten an Chemotherapie-induzierten neuropathischen Schmerzen (CINP) in Form von bleibenden Schmerzen und Taubheitssymptomen – eine schwerwiegende Beeinträchtigung ihrer Lebensqualität. Die Deutsche…
Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.
Bensheim, 18.10.2023 – Zum Deutschen Schmerzkongress in Mannheim kündigt Avextra seine Allianz für Evidenz mit dem Start von BELCANTO an: der ersten von Avextra unterstützten klinischen Studie für Onkologiepatient:innen. Zum…
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…
Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie
Auf dem virtuellen Deutschen Schmerz und Palliativtag im März haben Avextra und die Deutsche Gesellschaft für Schmerzmedizin (DGS) in einem Symposium ihre Pläne für eine gemeinsame prospektive, nicht-interventionelle, 12-wöchige Parallelgruppenstudie…
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…
Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.
Heute ist ein historischer Tag in Deutschland, an dem große Fortschritte bei der Entstigmatisierung der Cannabispflanze gemacht wurden. Martha Lurther, CSO bei Avextra, teilt ihre Gedanken zu den deutschen Plänen.…
Avextra AG Announces Closing of EU 17 Million Capital Raise
Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…
German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN
Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to…
AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU
Strategic partnership deepens Research & Development of medicinal cannabis in areas such as clinical trials, development of medical devices, and extraction methodologies. Avextra will actively participate in the supervision of…
Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients
Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim…
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…
Germany unveils scaled-down recreational cannabis legalization plan
Today marked a historic day in Germany as major strides were made in removing the stigma surrounding this plant. Martha Lurther, CSO at Avextra shares her thoughts on Germany’s plans.…
Avextra AG Announces Closing of EU 17 Million Capital Raise
Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…